Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series
Open Access
- 1 July 2009
- journal article
- case report
- Published by Springer Nature in BMC Neurology
- Vol. 9 (1) , 28
- https://doi.org/10.1186/1471-2377-9-28
Abstract
Chronic fatigue syndrome (CFS) is a disease of unknown aetiology. A patient with CFS had unexpected, marked recovery of CFS symptoms lasting for five months during and after cytotoxic chemotherapy for Hodgkin's disease. We reasoned that the transient CFS recovery was related to methotrexate treatment, which induces immunomodulation in part through B-cell depletion.Keywords
This publication has 32 references indexed in Scilit:
- Immunological aspects of chronic fatigue syndromeAutoimmunity Reviews, 2009
- B‐lymphocyte contributions to human autoimmune diseaseImmunological Reviews, 2008
- Immunoassay with cytomegalovirus early antigens from gene products p52 and CM2 (UL44 and UL57) detects active infection in patients with chronic fatigue syndromeJournal of Clinical Pathology, 2008
- Rituximab therapy in malignant lymphomaOncogene, 2007
- A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndromeQJM: An International Journal of Medicine, 2006
- Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritisArthritis & Rheumatism, 2006
- Evidence for the Presence of Immune Dysfunction in Chronic Fatigue SyndromeClinical and Vaccine Immunology, 2002
- High frequency of autoantibodies to insoluble cellular antigens in patients with chronic fatigue syndromeArthritis & Rheumatism, 1997
- Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome.Journal of Clinical Investigation, 1996
- Mime Combination Chemotherapy in Recurrent or Refractory Lymphoproliferative Malignancies: A Phase II StudyActa Oncologica, 1991